We would love to hear your thoughts about our site and services, please take our survey here.
"We've significantly advanced our bexmarilimab development program in 2022 and on this webcast, will provide updates on current trials and important milestones we expect to achieve over the coming months."
careful words from Markku with 'EXPECT' "and important milestones we expect to achieve over the coming months."
This is why the SP will be hammered.